ArticleScientific reports2025
Evaluation of Satanin 1 as a potential antifungal antimicrobial peptide to treat Malassezia infections.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Malassezia is a fungal genus that is part of the skin's normal mycobiota but can also cause various diseases. The emergence of resistance to antimicrobial agents in several microorganisms, including Malassezia yeasts, has led to the exploration of new therapeutic alternatives such as antimicrobial peptides. This study aimed to investigate the effect of Satanin 1, a recently identified antimicrobial peptide, against Malassezia using broth microdilution assays, Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM), and a Galleria mellonella infection model. Results showed that the Minimal Inhibitory Concentration (MIC) of Satanin 1 against Malassezia ranged from 50 to 12.5 µg/mL, and the peptide works by affecting the fungal cell surface. Nonetheless, Satanin 1 treatment did not improve the survival of infected G. mellonella, possibly due to an exacerbated immune response in the larvae, as shown by hemocyte population characterization and histopathological analyses. Continued investigation into alternative molecules, like antimicrobial peptides, is essential to combat the increasing threat of antifungal resistant microorganisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.